Login to Your Account

Clinic Roundup

Tuesday, March 1, 2011
4SC AG, of Planegg-Martinsried, Germany, reported final data from its ENTRANCE Phase IIa study of vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, in inflammatory bowel disease, which supported previously reported top-line primary endpoint data showing a total response rate of 88.5 percent. Secondary endpoint data included Crohn's Disease Activity Index and the Colitis Activity Index scores in line with the assignment of patients to the complete, partial and nonresponder categories. All 26 evaluable patients, excluding the three nonresponders, reached a relapse-free prednisolone dose significantly lower than their individual threshold doses at which they experienced relapses prior to entering the study.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription